Taiwan Clinical Trial Consortium for Renal Diseases

  • Fang, Ji-Tseng (PI)
  • Chang, Chih Hsiang (CoPI)
  • Chen, Yung Chang (CoPI)
  • Chen, Yung Ming (CoPI)
  • Chen, Jinn-Yang (CoPI)
  • Chen, Jin-Bor (CoPI)
  • Pan, Heng Chih (CoPI)
  • Tarng, Der Cherng (CoPI)
  • Wu, Vin Cent (CoPI)
  • Wu, Chih Jen (CoPI)
  • Wu, Kwan Dun (CoPI)
  • Yang, Ya-Fei  (CoPI)

Project: National Science and Technology CouncilNational Science and Technology Council Academic Grants

Project Details


The incidence rate of acute kidney injury (AKI) in hospitalized patients is increasing, and the number of deaths associated with dialysis-requiring AKI has more than doubled. Through strategies to lower the incidence of AKI and clarify the causal nature of the (acute kidney injury to chronic kidney disease) AKI-CKD relationship, further light will be shed on lowering the CKD burden by nipping it in the bud. CAKs will build a platform on which we share the clinical data and exchange state-of-the-art research information. Currently, the incidence rate of dialysis-requiring AKI is higher than that of end-stage renal disease (ESRD), and its annual growth rate is as high as 10% in the United States. To promote Taiwan Consortium of Acute Kidney Injury and Renal Diseases (CAKs) as the leading kidney diseases of clinical trial group in Asia-Pacific by establishing a cohesive group of kidney clinical trial sites that conduct uniform standard-of-care and high quality clinical trial performance in renal diseases and provide credible and reliable data. The participating investigators of CAKs are specialists of kidney medicine who have experience in conducting bench and clinical studies of kidney diasese. The key missions of the CAKs are to assist the design and conduct of multi-center investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of patients with kidney disease. Our central office provides the window of communication, database auditing and the improving quality of specimens, and core study coordination. Our core laboratory provides standardized analysis for novel AKI biomarkers. Participating subjects need to sign the informed consent for clinical data, PBMC/plasma/serum/ specimens from kidney biopsy. In the past three years, we have conducted 10 international clinical study, applied and finished 4 full ethical reviews by the institutional review board of NRPB. By estimation, the consortium has been demonstrated to have the ability to enroll patients with kidney disease and record the acute dialysis during intensive units. Core clinical information will continue to be collected using a web based information system for future analysis. The ultimate goal for CAKs is to enable clinical trials of potential therapies for kidney diseases and speed the development of treatments that will improve the severity of end stage renal disease and mortality for patients with kidney diseases.

Project IDs

Project ID:PC10703-0332
External Project ID:MOST106-2321-B182-002
Effective start/end date01/05/1730/04/18


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.